Structure-based virtual screening for the discovery of novel inhibitors of New Delhi metallo-β-lactamase-1

ACS Medicinal Chemistry Letters

Volumn , Issue , 2018, Pages 45-50

  Spyrakis, Francesca ^a,e   Celenza, Giuseppe ^b   Marcoccia, Francesca ^b   Santucci, Matteo ^a   Cross, Simon ^c   Bellio, Pierangelo ^b   Cendron, Laura ^d   Perilli, Mariagrazia ^b   Tondi, Donatella ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

Author keywords

4H 1 2 4 triazole 3 thiol derivatives; Bacterial resistance; Carbapenemases; Enzyme inhibition; NDM 1 Metallo lactamase; Structure based virtual screening

Indexed keywords

AMPICILLIN; BETA LACTAMASE INHIBITOR; CEFAZOLIN; CEFOTAXIME; MEROPENEM;

ARTICLE; BACTERIAL STRAIN; BINDING AFFINITY; COMPUTER MODEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SCREENING; GENE OVEREXPRESSION; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; NONHUMAN; PRIORITY JOURNAL;

EID: 85037839079     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/acsmedchemlett.7b00428     Document Type: Article

References (31)

1. WHO. Antimicrobial Resistance: Global Report on Surveillance, 2014. http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748-eng.pdf.
2. Frere, J. M.; Sauvage, E.; Kerff, F. From "An Enzyme Able to Destroy Penicillin" to Carbapenemases: 70 Years of Beta-lactamase Misbehaviour. Curr. Drug Targets 2016, 17 (9), 974-82.
3. Tondi, D.; Cross, S.; Venturelli, A.; Costi, M. P.; Cruciani, G.; Spyrakis, F. Decoding the Structural Basis For Carbapenem Hydrolysis By Class A beta-lactamases: Fishing For A Pharmacophore. Curr. Drug Targets 2016, 17 (9), 983-1005.
4. Tondi, D.; Venturelli, A.; Bonnet, R.; Pozzi, C.; Shoichet, B. K.; Costi, M. P. Targeting class A and C serine beta-lactamases with a broadspectrum boronic acid derivative. J. Med. Chem. 2014, 57 (12), 5449-58.
5. Mojica, M. F.; Bonomo, R. A.; Fast, W. B1-Metallo-beta- Lactamases: Where Do We Stand? Curr. Drug Targets 2016, 17 (9), 1029-50.
6. Ambler, R. P. The structure of beta-lactamases. Philos. Trans. R. Soc., B 1980, 289 (1036), 321-31.
7. Farina, D.; Spyrakis, F.; Venturelli, A.; Cross, S.; Tondi, D.; Costi, M. P. The inhibition of extended spectrum beta-lactamases: hits and leads. Curr. Med. Chem. 2014, 21 (12), 1405-34.
8. Bush, K.; Page, M. G. P. What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles. J. Pharmacokinet. Pharmacodyn. 2017, 44, 113-132.
9. Walsh, T. R.; Toleman, M. A.; Poirel, L.; Nordmann, P. Metallobeta- lactamases: the quiet before the storm? Clin Microbiol Rev. 2005, 18 (2), 306-25.
10. Fair, R. J.; Tor, Y. Antibiotics and bacterial resistance in the 21st century. Perspect. Med. Chem. 2014, 6, 25-64.
11. Poirel, L.; Lagrutta, E.; Taylor, P.; Pham, J.; Nordmann, P. Emergence of metallo-beta-lactamase NDM-1-producing multidrugresistant Escherichia coli in Australia. Antimicrob. Agents Chemother. 2010, 54 (11), 4914-6.
12. Nordmann, P.; Poirel, L.; Toleman, M. A.; Walsh, T. R. Does broad-spectrum beta-lactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria? J. Antimicrob. Chemother. 2011, 66 (4), 689-92.
13. Baroni, M.; Cruciani, G.; Sciabola, S.; Perruccio, F.; Mason, J. S. A common reference framework for analyzing/comparing proteins and ligands. Fingerprints for Ligands and Proteins (FLAP): theory and application. J. Chem. Inf. Model. 2007, 47 (2), 279-94.
14. Spyrakis, F.; Cellini, B.; Bruno, S.; Benedetti, P.; Carosati, E.; Cruciani, G.; Micheli, F.; Felici, A.; Cozzini, P.; Kellogg, G. E.; Voltattorni, C. B.; Mozzarelli, A. Targeting cystalysin, a virulence factor of treponema denticola-supported periodontitis. ChemMedChem 2014, 9 (7), 1501-11.
15. De Meester, F.; Joris, B.; Reckinger, G.; Bellefroid-Bourguignon, C.; Frere, J. M.; Waley, S. G. Automated analysis of enzyme inactivation phenomena. Application to β-lactamases and DD-peptidases. Biochem. Pharmacol. 1987, 36, 2393-2403.
16. Chen, A. Y.; Thomas, P. W.; Stewart, A. C.; Bergstrom, A.; Cheng, Z.; Miller, C.; Bethel, C. R.; Marshall, S. H.; Credille, C. V.; Riley, C. L.; Page, R. C.; Bonomo, R. A.; Crowder, M. W.; Tierney, D. L.; Fast, W.; Cohen, S. M. Dipicolinic Acid Derivatives as Inhibitors of New Delhi Metallo-beta-lactamase-1. J. Med. Chem. 2017, 60 (17), 7267-7283.
17. Klingler, F. M.; Wichelhaus, T. A.; Frank, D.; Cuesta-Bernal, J.; El- Delik, J.; Muller, H. F.; Sjuts, H.; Gottig, S.; Koenigs, A.; Pos, K. M.; Pogoryelov, D.; Proschak, E. Approved Drugs Containing Thiols as Inhibitors of Metallo-beta-lactamases: Strategy To Combat Multidrug- Resistant Bacteria. J. Med. Chem. 2015, 58 (8), 3626-30.
18. Groundwater, P. W.; Xu, S.; Lai, F.; Varadi, L.; Tan, J.; Perry, J. D.; Hibbs, D. E. New Delhi metallo-beta-lactamase-1: structure, inhibitors and detection of producers. Future Med. Chem. 2016, 8 (9), 993-1012.
19. Sevaille, L.; Gavara, L.; Bebrone, C.; De Luca, F.; Nauton, L.; Achard, M.; Mercuri, P.; Tanfoni, S.; Borgianni, L.; Guyon, C.; Lonjon, P.; Turan-Zitouni, G.; Dzieciolowski, J.; Becker, K.; Benard, L.; Condon, C.; Maillard, L.; Martinez, J.; Frere, J. M.; Dideberg, O.; Galleni, M.; Docquier, J. D.; Hernandez, J. F. 1, 2, 4-Triazole-3-thione Compounds as Inhibitors of Dizinc Metallo-beta-lactamases. ChemMedChem 2017, 12 (12), 972-985.
20. Nauton, L.; Kahn, R.; Garau, G.; Hernandez, J. F.; Dideberg, O. Structural insights into the design of inhibitors for the L1 metallo-betalactamase from Stenotrophomonas maltophilia. J. Mol. Biol. 2008, 375 (1), 257-69.
21. Jin, W.; Arakawa, Y.; Yasuzawa, H.; Taki, T.; Hashiguchi, R.; Mitsutani, K.; Shoga, A.; Yamaguchi, Y.; Kurosaki, H.; Shibata, N.; Ohta, M.; Goto, M. Comparative study of the inhibition of metallo-betalactamases (IMP-1 VIM-2) by thiol compounds that contain a hydrophobic group. Biol. Pharm. Bull. 2004, 27 (6), 851-6.
22. King, D. T.; Worrall, L. J.; Gruninger, R.; Strynadka, N. C. New Delhi metallo-beta-lactamase: structural insights into beta-lactam recognition and inhibition. J. Am. Chem. Soc. 2012, 134 (28), 11362-5.
23. Antony, J.; Gresh, N.; Olsen, L.; Hemmingsen, L.; Schofield, C. J.; Bauer, R. Binding of D- and L-captopril inhibitors to metallo-betalactamase studied by polarizable molecular mechanics and quantum mechanics. J. Comput. Chem. 2002, 23 (13), 1281-96.
24. Hopkins, A. L.; Keseru, G. M.; Leeson, P. D.; Rees, D. C.; Reynolds, C. H. The role of ligand efficiency metrics in drug discovery. Nat. Rev. Drug Discovery 2014, 13 (2), 105-21.
25. Milletti, F.; Storchi, L.; Goracci, L.; Bendels, S.; Wagner, B.; Kansy, M.; Cruciani, G. Extending pKa prediction accuracy: highthroughput pKa measurements to understand pKa modulation of new chemical series. Eur. J. Med. Chem. 2010, 45 (9), 4270-9.
26. Wade, R. C.; Goodford, P. J. The role of hydrogen-bonds in drug binding. Prog. Clin Biol. Res. 1989, 289, 433-44.
27. Huang, N.; Shoichet, B. K.; Irwin, J. J. Benchmarking sets for molecular docking. J. Med. Chem. 2006, 49 (23), 6789-801.
28. Marcoccia, F.; Bottoni, C.; Sabatini, A.; Colapietro, M.; Mercuri, P. S.; Galleni, M.; Kerff, F.; Matagne, A.; Celenza, G.; Amicosante, G.; Perilli, M. Kinetic Study of Laboratory Mutants of NDM-1 Metallobeta- Lactamase and the Importance of an Isoleucine at Position 35. Antimicrob. Agents Chemother. 2016, 60 (4), 2366-72.
29. Bellio, P.; Segatore, B.; Mancini, A.; Di Pietro, L.; Bottoni, C.; Sabatini, A.; Brisdelli, F.; Piovano, M.; Nicoletti, M.; Amicosante, G.; Perilli, M.; Celenza, G. Interaction between lichen secondary metabolites and antibiotics against clinical isolates methicillin-resistant Staphylococcus aureus strains. Phytomedicine 2015, 22 (2), 223-30.
30. Greco, W. R.; Bravo, G.; Parsons, J. C. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev. 1995, 47 (2), 331-85.
31. Odds, F. C. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 2003, 52 (1), 1.